New CF Triple Therapy Cuts Inflammation 60% Long-Term

For the first time, doctors have proof that a powerful triple drug therapy doesn't just help cystic fibrosis patients breathe easier today. It protects their lungs for years to come.

Cystic fibrosis affects more than 8,000 people in Germany alone, with 150 to 200 babies born with the inherited disease each year. The condition causes thick mucus to clog the lungs, leading to repeated infections that slowly damage breathing ability over time.

Until 2020, doctors could only treat the symptoms with mucus thinners and antibiotics. Then came a game changer: a triple combination drug called ETI that actually helps fix the underlying problem by improving how cells move salt and water.

Researchers at Hannover Medical School wanted to know if this triple therapy truly worked in the real world, not just controlled lab studies. They tracked 198 patients aged 6 and up for two full years, measuring inflammation markers in their blood alongside lung function.

The results stunned even the scientists. After just three months, inflammation levels dropped to 40% to 80% of where they started. Even better, those improvements stuck around for the entire two year study period.

"We're showing for the first time in everyday care that triple therapy not only relieves the lungs, but also reduces systemic inflammation in the long term," says Professor Anna-Maria Dittrich, who led the research team. The study included over 2,000 patients, making the findings especially reliable.

The Ripple Effect

This isn't just about numbers on a chart. Lower inflammation means less tissue damage over time, which is crucial for young patients whose entire futures depend on keeping their lungs healthy. Parents can now plan family vacations and school activities with more confidence, knowing their children's disease is being controlled at a deeper level.

The triple therapy works for 85% to 90% of cystic fibrosis patients in Germany who share the same genetic mutation. That's thousands of families who can finally see a path forward beyond just managing day-to-day symptoms.

The research team notes that some patients still showed residual inflammation, meaning there's room for improvement. They're already exploring whether adding targeted anti-inflammatory treatments could push results even further.

For now, though, families have something they desperately needed: solid proof that this treatment protects their loved ones not just today, but for years ahead.